Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

Poster: ST-503 nonclinical safety studies evaluating zinc finger repressors regulating expression of the Nav1.7 gene for treatment of small fiber neuropathy

Download PDF